Novo Holdings A/S and Pfizer Inc. invest in TherAchon Holding AG

TherAchon Holding AG, based in Basle-Stadt, has completed an USD 60 million Series B capital round. The round was led by Novo Holdings A/S and included, inter alia, Pfizer Inc. TherAchon develops a novel protein therapy for achondroplasia, the most common form of short-limbed dwarfism. 

The financing round was successfully completed by the end of July 2018.

Lenz & Staehelin advised Novo Holdings A/S, Pfizer Inc. and four other new investors in this transaction. The Lenz & Staehelin team included partner Andreas Rötheli and associate Federico Trabaldo Togna (both Corporate and M&A).